Suppr超能文献

碳水化合物介导的抗原靶向树突状细胞可增强抗原向T细胞的呈递。

Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.

作者信息

Adams Eddie W, Ratner Daniel M, Seeberger Peter H, Hacohen Nir

机构信息

Center for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy and Immununology, Massachusetts General Hospital and Harvard Medical School, Building 149, 13th Street, Charlestown, MA 02129, USA.

出版信息

Chembiochem. 2008 Jan 25;9(2):294-303. doi: 10.1002/cbic.200700310.

Abstract

The unique therapeutic value of dendritic cells (DCs) for the treatment of allergy, autoimmunity and transplant rejection is predicated upon our ability to selectively deliver antigens, drugs or nucleic acids to DCs in vivo. Here we describe a method for delivering whole protein antigens to DCs based on carbohydrate-mediated targeting of DC-expressed lectins. A series of synthetic carbohydrates was chemically-coupled to a model antigen, ovalbumin (OVA), and each conjugate was evaluated for its ability to increase the efficiency of antigen presentation by murine DCs to OVA-specific T cells (CD4(+) and CD8(+)). In vitro data are presented that demonstrate that carbohydrate modification of OVA leads to a 50-fold enhancement of presentation of antigenic peptide to CD4(+) T cells. A tenfold enhancement is observed for CD8(+) T cells; this indicates that the targeted lectin(s) can mediate cross-presentation of antigens on MHC class I. Our data indicate that the observed enhancements in antigen presentation are unique to OVA that is conjugated to complex oligosaccharides, such as a high-mannose nonasaccharide, but not to monosaccharides. Taken together, our data suggest that a DC targeting strategy that is based upon carbohydrate-lectin interactions is a promising approach for enhancing antigen presentation via class I and class II molecules.

摘要

树突状细胞(DCs)在治疗过敏、自身免疫和移植排斥方面具有独特的治疗价值,这取决于我们在体内将抗原、药物或核酸选择性递送至DCs的能力。在此,我们描述了一种基于碳水化合物介导靶向DC表达的凝集素将完整蛋白质抗原递送至DCs的方法。一系列合成碳水化合物被化学偶联至模型抗原卵清蛋白(OVA),并评估每个偶联物增加小鼠DCs向OVA特异性T细胞(CD4(+)和CD8(+))呈递抗原效率的能力。所呈现的体外数据表明,OVA的碳水化合物修饰导致向CD4(+) T细胞呈递抗原肽的效率提高50倍。对于CD8(+) T细胞观察到10倍的提高;这表明靶向凝集素可介导抗原在MHC I类分子上的交叉呈递。我们的数据表明,观察到的抗原呈递增强对于与复杂寡糖(如高甘露糖九糖)偶联的OVA是独特的,而对于单糖则不然。综上所述,我们的数据表明基于碳水化合物-凝集素相互作用的DC靶向策略是通过I类和II类分子增强抗原呈递的一种有前景的方法。

相似文献

2
Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Mol Immunol. 2009 Dec;47(2-3):164-74. doi: 10.1016/j.molimm.2009.09.026. Epub 2009 Oct 8.
7
The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.
Blood. 2012 Mar 8;119(10):2284-92. doi: 10.1182/blood-2011-08-373944. Epub 2012 Jan 10.
8
Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.
J Immunol. 2010 Sep 15;185(6):3426-35. doi: 10.4049/jimmunol.1001205. Epub 2010 Aug 20.
9
Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I.
Front Immunol. 2018 Jun 14;9:1231. doi: 10.3389/fimmu.2018.01231. eCollection 2018.
10
Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
J Control Release. 2012 May 30;160(1):88-95. doi: 10.1016/j.jconrel.2012.02.007. Epub 2012 Feb 15.

引用本文的文献

1
A lyophilizable LNP vaccine enables STING-reinforced postoperational adjuvant immunotherapy.
J Nanobiotechnology. 2025 May 26;23(1):379. doi: 10.1186/s12951-025-03445-4.
2
Immunological and Toxicological Assessment of Triterpenoid Saponins Bearing Lewis-X- and QS-21-Based Trisaccharides.
Chemistry. 2025 May 19;31(28):e202500994. doi: 10.1002/chem.202500994. Epub 2025 Apr 21.
5
Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications.
Pharmaceutics. 2022 Oct 26;14(11):2300. doi: 10.3390/pharmaceutics14112300.
8
Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin.
Front Immunol. 2021 Oct 21;12:732298. doi: 10.3389/fimmu.2021.732298. eCollection 2021.
9
Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment.
Biomacromolecules. 2020 Sep 14;21(9):3704-3712. doi: 10.1021/acs.biomac.0c00812. Epub 2020 Aug 20.

本文引用的文献

1
Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN.
Int Immunol. 2006 May;18(5):741-53. doi: 10.1093/intimm/dxl011. Epub 2006 Mar 28.
3
Tools for glycomics: mapping interactions of carbohydrates in biological systems.
Chembiochem. 2004 Oct 4;5(10):1375-83. doi: 10.1002/cbic.200400106.
4
Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens.
Immunol Rev. 2004 Jun;199:9-26. doi: 10.1111/j.0105-2896.2004.00142.x.
6
Recognition of microbial infection by Toll-like receptors.
Curr Opin Immunol. 2003 Aug;15(4):396-401. doi: 10.1016/s0952-7915(03)00080-3.
7
Tolerogenic dendritic cells.
Annu Rev Immunol. 2003;21:685-711. doi: 10.1146/annurev.immunol.21.120601.141040. Epub 2001 Dec 19.
9
Mycobacteria target DC-SIGN to suppress dendritic cell function.
J Exp Med. 2003 Jan 6;197(1):7-17. doi: 10.1084/jem.20021229.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验